(Q45735357)

English

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.

scientific article published on 10 October 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

0 references

1 reference

based on heuristic

inferred from title

Dominique Costagliola

object named as

D Costagliola

3

0 references

author name string

S Abgrall

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

C Rabaud

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Clinical Epidemiology Group of the French Hospital Database on HIV

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

language of work or name

0 references

publication date

10 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

1747-1755

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Toxoplasmic encephalitis in AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Survivor treatment selection bias in observational studies: examples from the AIDS literature

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45735357&oldid=1586625491"